Aldeyra Therapeutics (ALDX) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 62.7% versus a loss of 83.1%. Aldeyra Therapeutics is the larger company by market cap ($57.2 million vs $54.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | ZYBT |
|---|---|---|
| Share price | $0.9477 | $1.15 |
| Market cap | $57.17M | $54.50M |
| 1-day change | -1.14% | -0.87% |
| YTD return | -81.70% | -0.01% |
| 1-year return | -83.14% | -62.67% |
| 5-year return | -88.64% | — |
| EPS (TTM) | $-0.38 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $8.01 |
| 52-week low | $0.862 | $0.616 |
| Distance from 52-week high | -84.02% | -85.64% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +596.42% | — |
| Average volume | 1.18M | 5.10M |
| Shares outstanding | 60.33M | 47.39M |
| Employees | 6 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed ALDX by 20.5 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
ALDX vs ZYBT FAQ
Which is bigger, Aldeyra Therapeutics or Zhengye Biotechnology?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $57.17M compared with $54.50M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, ALDX or ZYBT?
ZYBT returned -62.67% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.